Portnoy Law: Lawsuit Filed On Behalf of Johnson & Johnson Consumer, Inc. Investors

Click here to join the case

Investors are encouraged to contact attorney Lesley F. Portnoy , to determine eligibility to participate in this action, by phone 310-692-8883 or email , or click here to join the case.

It is alleged in this complaint that J&J failed to include labeling informing consumers that the sunscreens may contain benzene as an active or inactive ingredient, which rendered the products misbranded, adulterated and unlawful for sale. It is also alleged in this complaint that J&J's conduct caused economic damages to the plaintiffs, who had relied on the ingredient list and advertising when deciding whether to purchase the sunscreen.

J&J admitted on July 14, 2021 that the products were unfit to sell due to unsafe levels of benzene, initiating a voluntary recall of five aerosol sunscreens. All lots of these five products have been recalled by J&J.

"Johnson & Johnson continued to market these sunscreen products as safe and healthy for consumers after being alerted to dangerous levels of a known, cancer-causing chemical," said Keller Lenkner Partner Warren Postman. "Companies that knowingly sell cancer-causing products to the public should face serious consequences for their actions, and we will pursue all available remedies for consumers who were injured by Johnson & Johnson's disregard for public health."

Please visit our website to review more information and submit your transaction information.

The Portnoy Law Firm represents investors in pursuing claims arising from corporate wrongdoing. The Firm's founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.

Lesley F. Portnoy, Esq.
Admitted CA and NY Bar
lesley@portnoylaw.com
310-692-8883
www.portnoylaw.com

Attorney Advertising


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

The Conversation (0)
Seegnal (TSXV:SEGN)

Seegnal Presents Real-World Evidence on Reducing Fall Risk in Geriatric Patients at Caltcm Summit

Seegnal Inc. (TSXV: SEGN) ("Seegnal" or the "Corporation"), a global leader in AI-enhanced prescription intelligence, today announced real-world clinical results demonstrating how medication governance may reduce fall-risk drivers in older adults -- a significant clinical and financial challenge... Keep Reading...
Cardiologist wearing virtual reality glasses.

Top 3 Medical Device ETFs for Investors in 2026

Exchange-traded funds (ETFs) are a popular investment strategy, and generally contain a variety of publicly traded companies under one stock symbol, often with a focus on a specific sector.Depending on the ETF, investors may be able to track up-and-coming companies, get exposure to top firms or... Keep Reading...
Stethoscope connected to a phone with medical data overlay.

Top 3 Small-cap Medical Device Stocks (Updated January 2026)

The growing prevalence of chronic diseases like cancer and diabetes is driving increasing innovation in medical device technology. In 2024 alone, 30 new devices were approved by the US Food and Drug Administration (FDA).Wearable medical devices and the use of artificial intelligence in medical... Keep Reading...
Scientists working in a modern medical research laboratory.

Pathways to Commercialising Biotech Innovations

In the medical technology industry, innovation is only the first step. While key to long-term success, innovation is only as good as a company’s commercialisation strategy. Once a technology has been developed and proven, the organisation must then embark on a process to commercialise it for... Keep Reading...
Medical devices on a desk.

How to Invest in Medical Device Stocks and ETFs

The medical device market offers investors unique exposure to the overall life science space, especially in an era of fast-growing tech advancements in healthcare.This industry covers a wide range of health and medical instruments and equipment used in the treatment, mitigation, diagnosis and... Keep Reading...
illustration of brain and cell phone.

BlinkLab Completes First Patient Test for US Autism Diagnostic Study

Digital healthcare company BlinkLab (ASX:BB1) has tested the first patient in its US autism diagnostic study, which is geared at validating the company's Dx1 test as a diagnostic aid for clinicians. BlinkLab states in its Wednesday (March 12) release that the study is the largest digital... Keep Reading...

Interactive Chart

Latest Press Releases

Related News